The role of ovarian ablation in the of management of breast cancer

Breast Journal

Volumn 11, Issue 6, 2005, Pages 416-424

  Wirk, Baldeep ^a  

^a MAYO CLINIC   (United States)

Author keywords

Ablation; Breast cancer; Ovarian; Premenopausal

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GOSERELIN; LEUPRORELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; GENE MUTATION; HUMAN; OVARIECTOMY; OVARY; OVARY CANCER; OVARY FUNCTION; PREMENOPAUSE; RISK REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN ANTAGONISTS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GOSERELIN; HUMANS; MIDDLE AGED; OVARY; PREMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 28544437102     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2005.00122.x     Document Type: Article

References (42)

1. Schinzinger A. Ueber carcinoma mammae [abstract]. 18th Congress of the German Society for surgery. Beilage Zum Centralblatt Fur Chirurgie 1889;16:55-66.
2. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
3. Boyd S. On oophorectomy in the treatment of cancer. BMJ 1897;2:890-96.
4. Ford D, Easton D, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 gene in breast cancer families. Am J Hum Genet 1998;62:676-89.
5. Struewing J, Hartage P, Wachholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
6. Eastern D, Narod S, Ford D, Steel M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. Lancet 1994;344:761.
7. Meijers-Heijboer H, VanGeel B, van Putten W, et al. Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 or BRCA2 mutations. N Engl J Med 2001;345:159-64.
8. Kauff N, Stagopan J, Robson M, et al. Risk-reducing salpingooophorectomy in women with BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1609-15.
9. Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
10. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
11. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP P-1) breast cancer prevention trial. JAMA 2001;286:2251-56.
12. Lerman C, Hughes C, Croyle R, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000;31:75-80.
13. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-68.
14. Meijers-Heijboer E, Verhoog L, Brekelmans C, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000;355:2015-20.
15. Pujol P, Daures J, Thezanas S, Guilleux F, Rouanet P, Grenier J. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998;83:698-705.
16. Walker R, Lees E, Webb M, Bearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996;74:1796-800.
17. Kallias J, Elston C, Ellis I, Robertson JF, Blarney RW. Early onset breast cancer-histopathological and prognostic considerations. Br J Cancer 1997;75:1318-23.
18. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with estrogen receptor breast cancer? Lancet 2000;35:1869-74.
19. Bianco A, Del Mastro L, Gallo L, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991;63:799-803.
20. Emens L, Davidson N. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003;9(1):486S-94.
21. Ball J. Age-associated incidence of chemotherapy related amenorrhea (CRA) following adjuvant doxorubicin, cyclophosphamide and paclitaxel (AC/Taxol) in early stage breast cancer [abstract 1810]. Presented at the American Society of Clinical Oncology 2001 annual meeting.
22. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
23. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: an overview of randomized trials. Lancet 1996;348:1189-96.
24. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: overview of randomized trials. Lancet 1998;351:1451-67.
25. Thomson C, Twelves C, Mallon E, et al. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of estrogen receptor status. Breast 2002;11:419-29.
26. Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide, methotrexate, fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE study (Takeda adjuvant breast cancer study with leuprorelin acetate). Anticancer Res 2002;22:2325-32.
27. Jonat W, Kaufman M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628-35.
28. Castiglione-Gertsch M, O'Neill A, Price K, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1835-46.
29. Roche H, Kerbrat P, Bonnetere J, et al. Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients with positive hormone receptors and 1-3 node positive tumor: Results of the FASG 06 trial [abstract 279]. Proc Am Soc Clin Oncol 2000;19:72a.
30. Davidson N, O'Neill A, Vukov A, et al. Chemohormonal therapy in premenopausal node positive, rceptor positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial E5188, INT0101 [abstract 15]. Proc Am Soc Clin Oncol 2003;22:5.
31. Baum M, Houghton J, Odling-Smee W. Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP trial. Breast 2001;10(suppl. 1):S23-33.
32. International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node positive, endocrine-responsive breast cancer? First results of the International Breast Cancer Study Group Trial 11-93. Breast 2001;10:130-38.
33. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-27.
34. Klijn J, Blarney R, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
35. Blamery R, Jonat W, Kaufman M, et al. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1992;28:810-14.
36. Miller W, Scott W, Morris R, et al. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985;313:231-33.
37. Klijn J, Berns P, Bontenbal M, et al. Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 1992;43:211-21.
38. Williamson K, Robertson J, Ellis I, et al. Effect of LHRH agonist, Zoladex, on ovarian histology. Br J Surg 1988;75:595-96.
39. Baum M, Budzar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: results of the ATAC (Arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 2003;98:1779-81.
40. Goldhirsch A, Wood W, Gelber R, et al. Meeting highlights. Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
41. Goldhirsch A, Gelber R, Yothers G, et al. Adjuvant therapy for young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001;30:44-51.
42. Blamey RW, EUSOMA. Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer 2002;38:615-34.